Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
Cosimo Bruni, Roberta Bitti, Francesca Nacci, Laura Cometi, Lorenzo Tofani, Francesca Bartoli, G. Fiori, Marco Matucci‐Cerinic
Topics & Concepts
MedicinePsoriatic arthritisInternal medicineAdalimumabConcomitantRheumatologyAdverse effectCohortRheumatoid arthritisBiosimilarPsoriasisPhysical therapyImmunologyBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and Treatments